Clinical trials: Insulin Pump
Type1 Diabetes Mellitus
A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® Delivered by an Insulin Pump
This is a single-centre, randomised, double-blind, three-period, complete cross-over trial comparing the pharmacokinetic and the pharmacodynamic properties of BioChaperone® insulin lispro and the two active comparators Fiasp® and…
- Trial name
- NCT03179332
- Testing
- BioChaperone® insulin lispro, Fiasp®, Novorapid®
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- Adocia
Type 1 Diabetes
Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration
The purpose of this study is to evaluate the effectiveness of insulin delivered in the peritoneum (abdomen)by an implantable pump in Type 1 diabetics.
- Trial name
- MIP310 (NCT00211536)
- Testing
- Medtronic MiniMed Implantable Pump Human Recombinant Insulin, Medtronic MiniMed Implantable Pump System, Aventis HOE21PH U400
- Where
- 5 sites in United States
- Volunteers
- 107 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes, Type 2 Diabetes
User Evaluation of the MiniMed 620G and 640G Insulin Pumps
This six center international study will include two United Kingdom National Health Service centers, two centers in Melbourne, Australia and one center each in Denmark and Spain.
- Trial name
- NCT01726621
- Testing
- Medtronic MiniMed 620G or 640G Insulin Pump
- Where
- 6 sites in Australia, Denmark and 2 more
- Volunteers
- 55 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes, Diabetes Mellitus, Type 1
A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes
The aim of the study is to compare the pharmacokinetics (i.e. the course of the blood concentrations of the administered trial drug) of faster-acting insulin aspart (faster aspart), and the currently marketed formulation of…
- Trial name
- NCT03215498
- Testing
- Faster-acting insulin aspart, Insulin aspart
- Where
- Germany
- Volunteers
- 58 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy
The reason for this study is to compare the study drug LY900014 to insulin lispro (Humalog) when both are used in insulin pump therapy in adults with type 1 diabetes (T1D).
- Trial name
- PRONTO-Pump-2 (NCT03830281)
- Testing
- Ultra-Rapid Lispro, Insulin Lispro
- Where
- 83 sites in United States, Australia and 9 more
- Volunteers
- 471 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes
Primary Objective: To compare Insuman Implantable 400 IU/ml versus Insuplant 400 IU/ml with respect to the pump refill accuracy during a 4 refill cycle period (i.e.
- Trial name
- NCT01194882
- Testing
- HUMAN INSULIN (BIOSYNTHETIC), Insuplant
- Where
- 17 sites in Belgium, France and 2 more
- Volunteers
- 479 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use
This is a 6-sequence, 3-period (8 weeks each), 3-arm, 24-week crossover study. The purpose of this study is to provide information on the use of insulin lispro in insulin pumps (Continuous Subcutaneous Insulin Infusion [CSII])…
- Trial name
- NCT01109316
- Testing
- Insulin lispro 2 day reservoir in-use, Insulin lispro 6 day reservoir in-use, Insulin aspart 6 day reservoir in-use
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1 Diabetes
Tandem Predictive Low Glucose Suspend Inpatient Feasibility Study
The goal of this study is to assess the functionality of an integrated predictive low glucose suspend system designed to minimize the incidence and duration of hypoglycemia by suspending insulin delivery if hypoglycemia is…
- Conditions
- Diabetes Mellitus, Type 1 Diabetes, Insulin Pump
- Trial name
- NCT02877771
- Testing
- t:slim insulin pump with predictive low glucose suspend
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes Mellitus
Self Operating of the ADI Insulin Pump By Intended Users - A Usability Study
Diabetes mellitus (DM) is a multisystem disease with both biochemical and anatomical consequences. Insulin pump therapy (continuous subcutaneous insulin infusion [CSII]) is an attractive way of treating patients with diabetes.
- Trial name
- NCT00592241
- Testing
- "Adi" Insulin Pump Usability
- Where
- Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- NiliMedix
Diabetes Mellitus, Type 1
SWITCH - Sensing With Insulin Pump Therapy to Control HbA1c
The primary objective of this study is to evaluate whether the patients with Type 1 diabetes mellitus in sub-optimal glycemic control can achieve better glycemic control by using the Medtronic MiniMed Paradigm® REAL-Time Pump…
- Trial name
- SWITCH (NCT00598663)
- Testing
- insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System), insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)
- Where
- 8 sites in Austria, Denmark and 5 more
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
Qingdao: Insulin Pump Follow-Up Program
The purpose of the study is to observe/ collect clinical data, subject users' feedback, and device data to better understand the real-life usage and acceptance of the 722 Pump in type 1 diabetes subjects,<18 years of age, and the…
- Trial name
- NCT02655666
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 1
DBLG1 System With TERUMO MEDISAFE WITH Insulin Pump Trial
This study conducted in 90 adults living with type 1 diabetes is an interventional single-arm open-label before/after multicentric national study conducted as a clinical investigation according to the law EU 2017/745 art. 62.
- Trial name
- BETTER (NCT05628532)
- Testing
- Use of the DBLG1 system
- Where
- 10 sites in France
- Volunteers
- 90 people
- Sponsor
- Diabeloop
Type 1 Diabetes
Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy
Primary Outcomes: Average decrease in A1c from baseline to end of Study Phase (52 weeks) for subjects in the "722 Group" is greater than that for subjects in the "Control (MDI) Group".
- Trial name
- STAR3 (NCT00417989)
- Testing
- MiniMed Paradigm REAL-Time System
- Where
- 30 sites in United States, Canada
- Volunteers
- 485 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes, Insulin Pump Users
Feasibility Study of the Solo™ Insulin Pump
The purpose of this study is to assess the safety and usability of the Solo™ insulin MicroPump in subjects with type 1 diabetes who are pump users.
- Trial name
- NCT01055951
- Testing
- Solo MicroPump
- Where
- 3 sites in Austria, Israel
- Volunteers
- 90 people
- Sponsor
- Medingo Ltd
Type 1 Diabetes
Performance Study of the SOLO 2.0 Insulin Pump
The Purpose of the study is to to evaluate the performance of the SOLO (version 2.0) micropump insulin delivery system, in Type 1 diabetic patients who use insulin pumps for their treatment.
- Trial name
- NCT01500928
- Testing
- SOLO insulin pump
- Where
- 2 sites in Israel
- Volunteers
- 40 people
- Sponsor
- Medingo Ltd
Diabetes
User Satisfaction Using the ADI Insulin Pump
Approximately 250,000 people worldwide are currently being treated with an insulin pump. This number is growing dramatically as these devices become smaller and more user-friendly.
- Trial name
- NCT00797771
- Testing
- "Adi" Insulin pump
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- NiliMedix
Diabetes Mellitus Type 2, Diabetes Mellitus Type 1
A Study Evaluating the Perception of Insertion Pain With Accu-Chek FlexLink and FlexLink Plus Insulin Pump Devices Under Real Life Conditions in Diabetic Patients.
German Multi-centered, randomized, crossover study in diabetic patients evaluating two infusion sets under real life conditions at home.
- Trial name
- NCT02103595
- Testing
- Accu-Chek FlexLink, Accu-Chek FlexLink Plus
- Where
- 5 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
Type1diabetes
Assessment of Two Insulin Pump Insulin Delivery Systems in Type 1 Diabetes.
This is a study of the Minimed 670G 4.0 insulin pump, assessing the efficacy of the Advanced Hybrid Closed Loop (AHCL) algorithm in controlling blood glucose levels in Type 1 Diabetes.
- Trial name
- NCT04073576
- Testing
- AHCL, SAP+PLGM
- Where
- New Zealand
- Volunteers
- 60 people
- Sponsor
- Christchurch Clinical Studies Trust Ltd
Diabetes Mellitus, Type 1
Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus
Primary objective: To demonstrate the superiority of insulin glulisine over insulin aspart and insulin lispro administered by external pump in term of unexplained hyperglycemia and/or infusion set occlusion.
- Trial name
- PUMP (NCT00607087)
- Testing
- Insulin glulisine, Insulin lispro, Insulin aspart
- Where
- 12 sites in United States, Australia and 10 more
- Volunteers
- 289 people
- Sponsor
- Sanofi
Type 1 Diabetes
Sigi Insulin Management System - A First-in-Human Study in Adults With Type 1 Diabetes
This early feasibility first-in-human study is a prospective single-arm single-center study of Sigi insulin patch pump. After a 1st day and night under medical surveillance during a hotel stay, Sigi system will be evaluated…
- Trial name
- SigiFIH (NCT05973422)
- Testing
- SIGI Insulin Management System
- Volunteers
- 10 people
- Sponsor
- Tandem Diabetes Care, Inc.